Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 15;208(2):212-213.
doi: 10.1164/rccm.202305-0843LE.

Reply to Lipworth and Chan

Christopher S Ambrose  1 , Elliot Israel  2 , Karin Bowen  3 , Jean-Pierre Llanos  4 , Neil Martin  5   6 , Bill Cook  1 , Åsa Hellqvist  7 , Stephanie Korn  8   9 , Andrew Menzies-Gow  5   10 , Stephanie L Roseti  3 , Nestor A Molfino  11 , Janet M Griffiths  12 , Jane R Parnes  13
Affiliations

Reply to Lipworth and Chan

Christopher S Ambrose et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

References

    1. Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of PATHWAY and NAVIGATOR studies. Am J Respir Crit Care Med . 2023;208:13–24. - PMC - PubMed
    1. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets . 2020;24:777–792. - PubMed
    1. Brusselle G, Riemann S. Is efficacy of tezepelumab independent of severe asthma phenotype? Am J Respir Crit Care Med . 2023;208:1–3. - PMC - PubMed
    1. Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, et al. Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond. Eur Respir J . 2023;61:2202202. - PubMed
    1. Busse WW. Consequences of severe asthma exacerbations. Curr Opin Allergy Clin Immunol . 2023;23:44–50. - PubMed